Infectious disease
It was a particularly busy week for announcements about clinical trials, both related to COVID-19 and everything else. Here’s a look.
The positive findings were shared as part of the company’s Emergency Use Authorization submission for its investigational COVID-19 therapy.
Fauci said the first COVID-19 vaccines could ship late December or early January.
BioSpace provides an up-to-date overview of these deals and the projected COVID-19 vaccine doses each company plans to have within the next couple of years.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Recent Greenphire data shows new participant enrollment up 85% since slump in April.
The report showed that in some cases, people who have recovered from the virus continued to exhibit significant cognitive deficits.
Pfizer indicated yesterday that its Phase III clinical trial of 44,000 volunteers now needs fewer than 2,000 people to be fully enrolled.
Novartis is harnessing the power of Molecular Partners AG’s DARPin platform to develop two therapeutic candidates that could both be used to prevent and treat COVID-19 infection.
Excess mortality rates in the U.S. remain high, despite a steady decline since mid-December.
PRESS RELEASES